A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)

NCT04669600 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune Thrombocytopenia (ITP)

Interventions

DRUG: SAR445088 (BIVV020)

Sponsor

Bioverativ, a Sanofi company